{"id":"oral-navelbine-carboplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Navelbine is a semi-synthetic vinca alkaloid that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest in cancer cells. Carboplatin is a platinum-based alkylating agent that forms DNA adducts and interstrand crosslinks, triggering apoptosis. The combination leverages two distinct mechanisms of cytotoxicity for enhanced anti-tumor effect.","oneSentence":"Oral Navelbine (vinorelbine) inhibits microtubule assembly to arrest cancer cell division, while carboplatin causes DNA crosslinking and cell death, together providing synergistic cytotoxic activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:44.506Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Advanced or metastatic solid tumors"}]},"trialDetails":[{"nctId":"NCT03456076","phase":"PHASE3","title":"A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-08-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":257},{"nctId":"NCT06564844","phase":"PHASE3","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":"Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm","enrollment":404},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT06355024","phase":"PHASE2","title":"Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2024-05-11","conditions":"Triple-negative Breast Cancer","enrollment":10},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT00312728","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer, Brain Neoplasms","enrollment":115},{"nctId":"NCT00887783","phase":"PHASE2","title":"Navelbine And Radiotherapy in Locally Advanced Lung Cancer","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2009-05-01","conditions":"Non-small Cell Lung Cancer","enrollment":117},{"nctId":"NCT03413579","phase":"PHASE3","title":"Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom","status":"COMPLETED","sponsor":"El Kendi Pharmaceuticals Manufacturing Company","startDate":"2015-11","conditions":"Cervical Cancer","enrollment":37},{"nctId":"NCT04681911","phase":"PHASE2","title":"Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2020-09-09","conditions":"Breast Cancer","enrollment":71},{"nctId":"NCT03656393","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2018-08-31","conditions":"NSCLC, EGFR","enrollment":48},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT02777788","phase":"PHASE2, PHASE3","title":"Curative Study of Chinese Traditional Medicine to Treat Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2014-09","conditions":"Cancer","enrollment":120},{"nctId":"NCT03203590","phase":"PHASE3","title":"Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2017-09","conditions":"2-year Disease-Free Survival","enrollment":590},{"nctId":"NCT00391586","phase":"PHASE2","title":"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT01683682","phase":"PHASE1","title":"An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)","status":"COMPLETED","sponsor":"Aktion Bronchialkarzinom e.V.","startDate":"2013-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":8},{"nctId":"NCT01038037","phase":"PHASE2","title":"First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Vejle Hospital","startDate":"2010-01","conditions":"Non Small Cell Lung Cancer","enrollment":23},{"nctId":"NCT00005838","phase":"PHASE3","title":"Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-03","conditions":"Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer","enrollment":756},{"nctId":"NCT00453635","phase":"PHASE2","title":"Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients","status":"TERMINATED","sponsor":"Hellenic Oncology Research Group","startDate":"2003-12","conditions":"Breast Cancer","enrollment":88},{"nctId":"NCT00737867","phase":"PHASE3","title":"Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"The Norwegian Lung Cancer Study Group","startDate":"2007-09","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":444},{"nctId":"NCT01258127","phase":"","title":"Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Shanghai Nancy Medical Sci-Tech Co. Ltd","startDate":"2010-08","conditions":"Non-small Cell Lung Cancer","enrollment":134},{"nctId":"NCT00272558","phase":"PHASE2","title":"Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2004-09","conditions":"Malignant Pleural Mesothelioma","enrollment":40},{"nctId":"NCT00300729","phase":"PHASE3","title":"Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy","status":"UNKNOWN","sponsor":"University Hospital, Linkoeping","startDate":"2006-05","conditions":"Non-Small Cell Lung Cancer","enrollment":319}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vinorelbine","Carboplat"],"phase":"phase_3","status":"active","brandName":"Oral Navelbine + Carboplatin","genericName":"Oral Navelbine + Carboplatin","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral Navelbine (vinorelbine) inhibits microtubule assembly to arrest cancer cell division, while carboplatin causes DNA crosslinking and cell death, together providing synergistic cytotoxic activity. Used for Non-small cell lung cancer (NSCLC), Advanced or metastatic solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}